Develops treatments for neurological diseases. Develops treatments for kidney diseases. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 25 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $32.8M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
On our five-subject report card, DMAC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: DMAC is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (42/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.